Skip to main content
Premium Trial:

Request an Annual Quote

Decode Posts Q2 Revenue Surge, Greater R&D Spending, and Widened Loss

NEW YORK, Aug. 14 - Decode genetics yesterday reported a surge in second-quarter total revenue and said that an increase in R&D spending caused the company's net loss to swell.


Total revenue for he period ended Jun 30 were $13.4 million, a 116-percent jump over the $6.2 million the company posted one year ago.


R&D spending in the quarter increased to $23.3 million from $16.3 million in the same quarter in 2001, in line with overall operating expenses, which grew to $29 million from $20 million in the second quarter 2001, Decode said.


As a result, the company recorded an increase in net losses in the quarter to $16.8 million, or $.32 per share, from $12.3 million, or $.28 per share, year over year.


Decode said it had roughly $121.4 million in cash and cash equivalents as of June 30.


Click here for more information.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.